ALLOGENE THERAPEUTICS INC

Company Overview

Allogene Therapeutics (ALLO) is a clinical-stage biotechnology company developing engineered allogeneic (donor-derived, off‑the‑shelf) CAR‑T therapies aimed at oncology and autoimmune indications. Lead programs include cema-cel (ALLO‑1501A) for large B‑cell lymphoma (pivotal ALPHA3 1L consolidation trial), ALLO‑1316 (CD70) for clear cell renal cell carcinoma (TRAVERSE, RMAT designated), and ALLO‑1329 (CD19/CD70) for autoimmune diseases (IND cleared, Phase 1 planned). The company combines in‑house protein engineering, gene editing and a Cell Forge cGMP facility with licensed technologies and CDMO relationships; its commercial value proposition is rapid, broadly distributable frozen inventory and potential cost/throughput advantages over autologous CAR‑T. Operations and valuation are heavily milestone‑driven (interim analyses, regulatory interactions, manufacturing scale‑up, and partner milestones).

Executive Compensation Practices

Compensation at Allogene is likely equity‑heavy and milestone‑linked, reflecting typical biotechnology structures and the company’s stated reliance on clinical and regulatory inflection points; 2024 stock‑based compensation expense was $51.7M with $69.2M unrecognized, and management specifically cited lower stock‑based comp as a driver of reduced spend. Cash base salaries and severance do matter (management disclosed a ~28% headcount reduction with ~$3.3M–$3.1M in severance in 2025), but long‑term incentives (RSUs/options, performance vesting tied to trial enrollment, interim readouts, BLA submissions, and partner milestones) will dominate senior pay to align executives with milestone delivery. Given the capital intensity and warning of future dilution, boards commonly use multi‑year performance vesting and retention awards for key R&D/manufacturing leaders to secure continuity through pivotal readouts and scale‑up. Impairment charges, cash runway guidance and financing needs will influence pay mix toward equity when cash conservation is prioritized.

Insider Trading Considerations

Insider trading patterns at Allogene will often cluster around clear company inflection points (ALPHA3 interim analyses and lymphodepletion arm selection, TRAVERSE durability readouts, ALLO‑1329 PoC data) and around financings—both times that insiders possess material nonpublic information. Watch for Form 4 filings before or after public milestone releases and equity raises; equity‑heavy compensation and multi‑year unrecognized awards create incentives for executives to time sales for liquidity, but such trades are subject to SEC scrutiny and commonly executed under 10b5‑1 plans and company blackout policies. Safety signals (e.g., the ALLO‑1647 Grade 5 adverse event and subsequent protocol changes) and manufacturing/CDMO setbacks are highly material — insiders must avoid trading on nonpublic safety/manufacturing information and may face additional legal/partner contract trading constraints. For traders and researchers, monitor: timing of 10b5‑1 plan disclosures, clustered sales near financing announcements, large option exercises/RSU vesting events, and any abrupt changes in insider behavior ahead of regulatory or clinical readouts.